Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000305521 | SCV000330809 | pathogenic | not provided | 2023-06-06 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Reported previously in two siblings with Carpenter syndrome who harbored a maternally inherited R28X; L145X complex allele in trans with a paternally inherited L145X variant (Jenkins et al., 2011); This variant is associated with the following publications: (PMID: 23599695, 21412941, 33368989) |
Labcorp Genetics |
RCV001034654 | SCV000637233 | pathogenic | Carpenter syndrome | 2024-02-17 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg28*) in the RAB23 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RAB23 are known to be pathogenic (PMID: 17503333, 21412941). This variant is present in population databases (rs765443042, gnomAD 0.007%). This premature translational stop signal has been observed in individual(s) with Carpenter syndrome, although in one family this variant was shown to be on the same chromosome (in cis) with another pathogenic variant (p.Leu145*) (PMID: 21412941, 23599695). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 280858). For these reasons, this variant has been classified as Pathogenic. |
Genetics and Molecular Pathology, |
RCV000546008 | SCV002761662 | likely pathogenic | RAB23-related Carpenter syndrome | 2022-03-02 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000546008 | SCV005673217 | pathogenic | RAB23-related Carpenter syndrome | 2024-03-13 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000546008 | SCV001453296 | pathogenic | RAB23-related Carpenter syndrome | 2020-09-16 | no assertion criteria provided | clinical testing | |
Prevention |
RCV003930036 | SCV004741156 | pathogenic | RAB23-related disorder | 2024-01-17 | no assertion criteria provided | clinical testing | The RAB23 c.82C>T variant is predicted to result in premature protein termination (p.Arg28*). This variant has been reported in six individuals from three families with Carpenter syndrome (Jenkins et al. 2011. PubMed ID: 21412941; Ben-Salem et al. 2013. PubMed ID: 23599695; Lodhia et al. 2021. PubMed ID: 33368989). In two of those individuals from one family, the c.434T>A and c.82C>T variant were reported to be on the same allele (cis orientation) with a nonsense variant on the other allele (Jenkins et al. 2011. PubMed ID: 21412941). In another family, both parents were heterozygous for the c.82C>T variant and the child with Carpenter syndrome was homozygous for the c.82C>T variant (Lodhia et al. 2021. PubMed ID: 33368989). Chain-terminating variants in RAB23 are expected to be pathogenic. Taken together, this variant is interpreted as pathogenic. |